Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.
Kazuki TakadaYasuto YoneshimaKentaro TanakaIsamu OkamotoMototsugu ShimokawaSho WakasuShinkichi TakamoriGouji ToyokawaTaro ObaAtsushi OsoegawaTetsuzo TagawaYoshinao OdaYoichi NakanishiMasaki MoriPublished in: Journal of cancer research and clinical oncology (2020)
L3 muscle index Low is an independent predictor of worse outcomes in NSCLC patients treated with anti-PD-1 inhibitors.